Drug Trial Radar · NCT07459660
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
210
Planned (sponsor's estimate)
Start
Mar 25, 2026
Primary completion
Mar 2029
Study completion Mar 2029
Sponsor
- Lead sponsor
- MapLight TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 91 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).
Conditions
- Psychosis Associated With Alzheimer's Disease
Interventions
ML-007C-MADrug
ML-007C-MA dosed as 105/1.5 mg BID or 210/3 mg BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the safety and tolerability of long-term ML-007C-MA administration in participants with hallucinations and delusions associated with ADTime frame: From initial dose through end of treatment (up to 52 weeks)
Locations
11 sites in 3 countries. Site status is shown where the registry gives one.
Clinical Site
Anaheim, California
Clinical Site
Denver, Colorado
Clinical Site
Doral, Florida
Clinical Site
Miami, Florida
Clinical Site
Miami, Florida
Clinical Site
Miami Gardens, Florida
Clinical Site
Orlando, Florida
Clinical Site
Snellville, Georgia
Clinical Site
Independence, Ohio
Clinical Site
Pernik, Pernik, Bulgaria
Clinical Site
Toulouse, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.